VTVT vTv Therapeutics Inc.

5.54
0  0%
Previous Close 5.56
Open 5.56
Price To book 0.00
Market Cap 53.70M
Shares 9,693,000
Volume 31,062
Short Ratio 11.81
Av. Daily Volume 23,144

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released August 2016. Primary endpoint met.
TTP399 - AGATA
Type 2 Diabetes
Phase 2 primary endpoint met - December 14, 2016.
TTP273 - LOGRA
Type 2 Diabetes
Phase 3 initiated 2Q 2015. Part A enrollment completed September 2016. Data from Part A due early 2018. Part B due late 2018.
Azeliragon - STEADFAST
Mild Alzheimer’s disease

Latest News

  1. ETFs with exposure to vTv Therapeutics, Inc. : April 5, 2017
  2. vTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 15, 2017
  3. vTv Therapeutics to Present at Two Upcoming Annual Investor Conferences
  4. VTv Therapeutics reports 4Q loss
  5. vTv Therapeutics Reports 2016 Fourth Quarter and Full Year Financial and Operational Results and Recent Highlights
  6. vTv Therapeutics (VTVT) in Focus: Stock Moves 6.7% Higher
  7. vTv Therapeutics Announces Positive Topline Results from Phase 2 Study of TTP273 in Type 2 Diabetes
  8. New Pre-Clinical Data on a vTv Therapeutics Small Molecule Drug Candidate Against Parkinson’s Disease to be Presented at the Society for Neuroscience 2016 Meeting in San Diego
  9. Can Agilent Technologies (A) Pull a Surprise in Q4 Earnings?
  10. vTv Therapeutics to Participate in Upcoming Mizuho, Stifel and Piper Jaffray Conferences
  11. ETF’s with exposure to vTv Therapeutics, Inc. : November 7, 2016
  12. vTv Therapeutics Reports Third Quarter Financial and Operational Results and Recent Highlights
  13. vTv Therapeutics to Present at Peptide Therapeutics Symposium
  14. vTv Therapeutics to Present at Neuro Advance Boston
  15. vTv Therapeutics Shares Initiated With Buy Rating, $13 Target
  16. vTv Therapeutics to Present at the Rodman & Renshaw Global Investment Conference
  17. vTv Therapeutics Completes Enrollment of Part A of Pivotal Phase 3 Trial Evaluating Azeliragon for the Treatment of Patients with Mild Alzheimer’s Disease
  18. vTv Therapeutics Completes Enrollment of Phase 2 Trial Evaluating TTP273 for the Treatment of Type 2 Diabetes